Bristol-Myers Squibb Profit Margin 2006-2018 | BMY

Current and historical gross margin, operating margin and net profit margin for Bristol-Myers Squibb (BMY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Bristol-Myers Squibb net profit margin as of September 30, 2018 is 6.5%.
Bristol-Myers Squibb Annual Profit Margins
Bristol-Myers Squibb Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $81.806B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.628B 16.44
Pfizer (PFE) United States $253.175B 14.27
Novartis AG (NVS) Switzerland $205.567B 17.62
Merck (MRK) United States $204.560B 17.73
AbbVie (ABBV) United States $134.627B 11.95
Eli Lilly (LLY) United States $123.506B 21.71
Novo Nordisk (NVO) Denmark $117.412B 19.07
Sanofi (SNY) France $104.035B 12.88
GlaxoSmithKline (GSK) United Kingdom $96.892B 13.02
AstraZeneca (AZN) United Kingdom $92.577B 11.49